Skip to content 
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. more
| Time Frame | VRTX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 2.99% | 1.51% | -1.5% |
| 1-Month Return | 7.97% | 1.46% | 0.6% |
| 3-Month Return | 9.98% | 3.94% | 2.43% |
| 6-Month Return | 22.43% | 16.03% | 6.01% |
| 1-Year Return | 3.29% | 9.1% | 11.48% |
| 3-Year Return | 62.54% | 19.46% | 67.52% |
| 5-Year Return | 122.16% | 35.29% | 73.75% |
| 10-Year Return | 440.87% | 137.42% | 254.46% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 7.57B | 8.93B | 9.87B | 11.02B | 12.00B | [{"date":"2021-12-31","value":63.11,"profit":true},{"date":"2022-12-31","value":74.41,"profit":true},{"date":"2023-12-31","value":82.23,"profit":true},{"date":"2024-12-31","value":91.82,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 904.20M | 1.08B | 1.26B | 1.53B | 1.63B | [{"date":"2021-12-31","value":55.43,"profit":true},{"date":"2022-12-31","value":66.23,"profit":true},{"date":"2023-12-31","value":77.38,"profit":true},{"date":"2024-12-31","value":93.83,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 6.67B | 7.85B | 8.61B | 9.49B | 10.35B | [{"date":"2021-12-31","value":64.45,"profit":true},{"date":"2022-12-31","value":75.85,"profit":true},{"date":"2023-12-31","value":83.16,"profit":true},{"date":"2024-12-31","value":91.69,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 88.06% | 87.90% | 87.21% | 86.11% | 86.24% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":99.03,"profit":true},{"date":"2024-12-31","value":97.78,"profit":true},{"date":"2025-12-31","value":97.93,"profit":true}] |
| Operating Expenses | 3.89B | 3.54B | 4.78B | 9.72B | 5.68B | [{"date":"2021-12-31","value":40.02,"profit":true},{"date":"2022-12-31","value":36.44,"profit":true},{"date":"2023-12-31","value":49.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":58.45,"profit":true}] |
| Operating Income | 2.78B | 4.31B | 3.83B | (232.90M) | 4.69B | [{"date":"2021-12-31","value":59.35,"profit":true},{"date":"2022-12-31","value":91.89,"profit":true},{"date":"2023-12-31","value":81.75,"profit":true},{"date":"2024-12-31","value":-4.97,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (108.30M) | 14.80M | 1.12B | 1.05B | - | [{"date":"2021-12-31","value":-9.68,"profit":false},{"date":"2022-12-31","value":1.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.79,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 2.73B | 4.23B | 4.38B | 248.50M | 4.64B | [{"date":"2021-12-31","value":58.8,"profit":true},{"date":"2022-12-31","value":91.15,"profit":true},{"date":"2023-12-31","value":94.33,"profit":true},{"date":"2024-12-31","value":5.35,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income Taxes | 388.30M | 910.40M | 760.20M | 784.10M | 690.00M | [{"date":"2021-12-31","value":42.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.5,"profit":true},{"date":"2024-12-31","value":86.13,"profit":true},{"date":"2025-12-31","value":75.79,"profit":true}] |
| Income After Taxes | 2.34B | 3.32B | 3.62B | (535.60M) | - | [{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-14.8,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 2.34B | 3.32B | 3.62B | (535.60M) | - | [{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-14.8,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 2.34B | 3.32B | 3.62B | (535.60M) | 3.95B | [{"date":"2021-12-31","value":59.25,"profit":true},{"date":"2022-12-31","value":84.03,"profit":true},{"date":"2023-12-31","value":91.56,"profit":true},{"date":"2024-12-31","value":-13.55,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 13.02 | 14.89 | 15.22 | 0.29 | 18.41 | [{"date":"2021-12-31","value":70.72,"profit":true},{"date":"2022-12-31","value":80.88,"profit":true},{"date":"2023-12-31","value":82.67,"profit":true},{"date":"2024-12-31","value":1.58,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| VRTX | |
|---|---|
| Cash Ratio | 1.71 |
| Current Ratio | 2.90 |
| Quick Ratio | 2.46 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| VRTX | |
|---|---|
| ROA (LTM) | 12.16% |
| ROE (LTM) | 22.54% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| VRTX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| VRTX | |
|---|---|
| Trailing PE | 32.06 |
| Forward PE | 25.13 |
| P/S (TTM) | 10.40 |
| P/B | 6.68 |
| Price/FCF | 358 |
| EV/R | 10.00 |
| EV/Ebitda | 25.79 |
| PEG | 0.58 |
Vertex Pharmaceuticals Inc (VRTX) share price today is $477.32
Yes, Indians can buy shares of Vertex Pharmaceuticals Inc (VRTX) on Vested. To buy
Yes, you can purchase fractional shares of Vertex Pharmaceuticals Inc (VRTX) via the Vested app. You can start investing in Vertex Pharmaceuticals Inc (VRTX) with a minimum investment of $1.
You can invest in shares of Vertex Pharmaceuticals Inc (VRTX) via Vested in three simple steps:
The 52-week high price of Vertex Pharmaceuticals Inc (VRTX) is $519.68. The 52-week low price of Vertex Pharmaceuticals Inc (VRTX) is $362.5.
The price-to-earnings (P/E) ratio of Vertex Pharmaceuticals Inc (VRTX) is 32.0594
The price-to-book (P/B) ratio of Vertex Pharmaceuticals Inc (VRTX) is 6.68
The dividend yield of Vertex Pharmaceuticals Inc (VRTX) is 0.00%
The market capitalization of Vertex Pharmaceuticals Inc (VRTX) is $124.83B
The stock symbol (or ticker) of Vertex Pharmaceuticals Inc is VRTX
Consider the share price of Vertex Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Vertex Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Vertex Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Vertex Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Vertex Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Vertex Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
